Physician profile
Brian H Black
NPI 1437255239
$3,115.57
in general payments reported to CMS, 2019-2025
29 companies · $838 in 2025
The $838 reported for 2025 was more than what 83% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $57.27 · 2021: $71.60 · 2022: $863 · 2023: $618 · 2024: $667 · 2025: $838.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,103 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,103.05 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $498.73 | 2022-2025 | Ubrelvy, Vraylar |
| Astrazeneca Pharmaceuticals LP | $381.94 | 2022-2025 | Farxiga, Airsupra, Breztri |
| Amgen INC. | $377.76 | 2019-2025 | Otezla, Repatha, Repatha |
| Novo Nordisk INC | $339.02 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Lilly USA, LLC | $261.05 | 2019-2025 | Mounjaro, Jardiance, Emgality |
| Exact Sciences Corporation | $140.84 | 2023-2024 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $124.34 | 2023-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $116.58 | 2025 | Caplyta |
| Glaxosmithkline, LLC. | $114.30 | 2022-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Novartis Pharmaceuticals Corporation | $105.87 | 2022-2023 | |
| Axsome Therapeutics, INC. | $105.19 | 2025 | Auvelity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $85.07 | 2022-2024 | Jardiance, Ofev |
| Sumitomo Pharma America, INC. | $71.58 | 2023-2024 | Gemtesa |
| Otsuka America Pharmaceutical, INC. | $55.79 | 2022-2024 | Rexulti |
| Sunovion Pharmaceuticals INC. | $43.97 | 2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $40.36 | 2022-2023 | Myrbetriq |
| Ultragenyx Pharmaceutical INC. | $40.12 | 2022-2023 | |
| Inspire Medical Systems, INC. | $27.05 | 2024 | Inspire |
| Kyowa Kirin, INC. | $21.72 | 2025 | |
| Abbott Laboratories | $20.81 | 2022 | |
| Amarin Pharma, INC. | $19.06 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.67 | 2022 | |
| Amneal Pharmaceuticals LLC | $17.21 | 2022 | |
| Radius Health, INC. | $16.97 | 2025 | Tymlos |
| Idorsia Pharmaceuticals US INC | $16.37 | 2023 | Quviviq |
| Biogen, INC. | $16.22 | 2022 | |
| Philips North America LLC | $14.34 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.06 | 2022 | |
| Ironshore Pharmaceuticals INC. | $11.58 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Black listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.